Market Size (2020)
$7.21B
Vertical: HealthcareBase Year: 2020
Market Size (2020)
$7.21B
Projected (2025)
$7.54B
CAGR (2020–2025)
0.9%
Key Players
100+
This report covers Stoma Ostomy Care Market with forecasts from 2020 to 2025. 100 key companies are profiled.
The Stoma Ostomy Care Market market is projected to grow at a CAGR of 0.9% from 2020 to 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansStoma Ostomy Care Market
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
Analysis of Stoma Ostomy Care Market from 2020 to 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2020
Historical Period
2020 – 2020
Forecast Period
2021 – 2025
Primary Interviews
150+
Historical data (2020–2020) and forecast period (2020–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Stoma Ostomy Care Market covering market dynamics, competitive landscape, and strategic outlook.
The Stoma Ostomy Care Market market is projected to reach $7.54B by 2025, growing at 0.9% CAGR.
The Stoma Ostomy Care Market market encompasses 0 key regions and multiple market segments, with the study period spanning 2020 to 2025. The market demonstrates a 0.9% compound annual growth rate, reflecting strong underlying demand fundamentals.
The market is segmented across multiple dimensions, with detailed breakdowns available by component, region, and application type to support strategic planning and investment decisions.
This report profiles 100 key companies operating in the Stoma Ostomy Care Market market, covering market positioning, product portfolios, and recent developments.
Leading players include , and 95 others.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 100 companies operating in the Stoma Ostomy Care Market market, including revenue, employee count, and market positioning where available.
Showing 100 of 100 companies
Novavax, Inc.
Company Headquarters: Maryland, US Founded: 1987 Workforce: ~2,500 Company Working: Novavax, Inc. is a biotechnology company that commercializes and develops vaccines to prevent a wide range of infectious diseases. It designs recombinant nanoparticle vaccine technology that produces a strong immune response against a variety of pathogens. It is partnered with leading biopharma organizations, government agencies, research institutions, and foundations, namely the Coalition for Epidemic Preparedness Innovations (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), the Serum Institute of India Pvt. Ltd. (India), SK Bioscience (South Korea), CPL Biological (India), and Takeda Pharmaceuticals (US). It has seven research and manufacturing facilities. It has presence in regions namely North America, Europe, and the Middle East and Africa
Cleveland Biolabs, Inc
Company Headquarters: New York, US Founded: 2003 Workforce: ~150 Company Working: Cleveland Biolabs, Inc. is an innovative biopharmaceutical company developing products to address immune system diseases and serious medical needs. It is specialized in offering products such as radiation injury products, immune-oncology, and orphan drugs. It has nine product candidates in its pipeline that have been developing directly through itself or its wholly owned companies, namely Incuron, LLC (US) and Panacela Labs, Inc. (US). It has a proprietary platform, namely the Advanced Immunomodulating Multi-Receptor System (AIMS) platform, which is designed to restore immune homeostasis. Moreover, it has collaboration with government agencies which supports the advanced development and procurement of new medical countermeasures including drugs, vaccines, diagnostics, and medical supplies in order to protect public health from chemical, biological, radiological, and nuclear threats.
SIGA Technologies
Company Headquarters: New York, US Founded: 1995 Workforce: ~50 Company Working: SIGA Technologies (SIGA) is a pharmaceutical business at the commercialization stage that develops and offers antiviral treatments for smallpox, monkeypox, cowpox, and vaccinia complications. The company has an established research and development collaboration with US federal entities. It provides countermeasures to the Strategic National Stockpile (SNS) and the Department of Defense (DoD). TPOXX ("oral TPOXX," also known as "tecovirimat" in certain overseas markets) is the Company's lead product, which it distributes to the US government and international governments (including government-affiliated entities). In addition, the Company sells TPOXX intravenous formulation ("IV TPOXX") to the US Government
Altimmune
Company Headquarters: Maryland, US Founded: 1997 Workforce: ~50 Company Working: Altimmune is a clinical-stage biopharmaceutical business focusing on treating obesity and liver illnesses. The business is working on HepTcell, an immunotherapeutic drug aimed at providing a functional cure for chronic hepatitis B. The company was formed through the merger of PharmAthene, Inc. ("PharmAthene") with the company formerly known as Altimmune
Bavarian Nordic
Company Headquarters: Denmark, Europe Founded: 1992 Workforce: ~1000 Company Working: Bavarian Nordic is a fully integrated vaccines company focused on R&D innovation, vaccine manufacturing, and vaccine commercialization. It has built a commercial infrastructure with a presence in key countries in Europe and the US in order to drive profitable expansion of its expanding vaccine portfolio. The company is an expert in the production of live viral vaccines, and the fill & finish capabilities has enabled end-to-end commercial-scale production
Navidea Biopharmaceuticals Inc
Company Headquarters: Ohio, US Founded: 1983 Workforce: ~ 50 Company Working: Navidea Biopharmaceuticals Inc (Navidea) manufacturer and distributor of precision immunodiagnostic agents and immunotherapeutic. It operates through mainly three segments such as diagnostics, therapeutics, and corporate. Tc99m tilmanocept for Kaposi's, NAS, cardiovascular illnesses, sentinel node biopsy, and solid tumors lymphatic mapping, as well as NAV4694 for Alzheimer's Disease, are among its pipeline products. The business is utilizing its Manocept platform to create a variety of precision-targeted solutions that will enhance patient care by locating illness pathways and sites and facilitating accurate clinical decision-making. Furthermore, it operates in the US and the UK.
3 interactive charts drawn from the Stoma Ostomy Care Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence